DNA Cytometry for Differentiation Between Low- and Mediumgrade Dysplasia in Intraductal Papillary Mucinous Neoplasms

Klein, Fritz; Denecke, Timm; Faber, Wladimir; Jürgensen, Christian; Schirmeier, Anja; Al-Abadi, H.; Walter, Thula; Al-Abadi, Nadine; Malinka, Thomas; Pratschke, Johann; Bahra, Marcus

doi:10.21873/anticanres.11371

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detection of such mutations can distinguish potentially harmful precursor lesions from benign cysts (such as serous cystadenomas), but at least to date, they do not reliably distinguish IPMNs with low-grade dysplasia from IPMNs with high-grade dysplasia. The assessment of ploidy by DNA cytometry may provide a simple method to suggest grade of dysplasia in IPMN cyst fluid 116 . However, more accurate markers (such as mutations in late driver genes like TP53 and SMAD4 ) will be required to distinguish cysts requiring immediate clinical intervention from those that can be safely monitored.…”

Section: Exploiting Molecular Alterations In the Clinical Settingmentioning

confidence: 99%

New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis

Felsenstein

Hruban

Wood

2018

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Pancreatic cancer is an aggressive disease with a dismal prognosis in dire need of novel diagnostic and therapeutic approaches. The past decade has witnessed an explosion of data on the genetic alterations that occur in pancreatic cancer, as comprehensive next-generation sequencing analyses have been performed on samples from large cohorts of patients. These studies have defined the genomic landscape of this disease and identified novel candidates whose mutations contribute to pancreatic tumorigenesis. They have also clarified the genetic alterations that underlie multistep tumorigenesis in precursor lesions and provided insights into clonal evolution in pancreatic neoplasia. In addition to these important insights into pancreatic cancer biology, these large scale genomic studies have also provided a foundation for the development of novel early detection strategies and targeted therapies. In this review, we discuss the results of these comprehensive sequencing studies of pancreatic neoplasms, with a particular focus on how their results will impact the clinical care of patients with pancreatic cancer.

show abstract

Section: Exploiting Molecular Alterations In the Clinical Settingmentioning

confidence: 99%